---
title: 'Scientist, Metabolism at NewLimit'
canonical: 'https://feeny.ai/job/scientist-metabolism-newlimit-south-san-francisco-5k9gbm6gpcwn'
type: 'job'
last_seen: '2026-09-26'
---

# Scientist, Metabolism at NewLimit

- **Company:** NewLimit
- **Location:** South San Francisco, CA
- **Posted:** 2026-09-25
- **Last confirmed live:** 2026-09-26
- **Apply:** https://job-boards.greenhouse.io/newlimit/jobs/6209015004

## Job description

Company info

NewLimit is a biotechnology company working to radically extend human healthspan. We’re developing medicines to treat age-related diseases by reprogramming the epigenome, a new therapeutic mechanism to restore regenerative potential in aged and diseased cells. We leverage functional genomics, pooled perturbation screening, and machine learning models to unravel the biology of epigenetic aging and disease using experiments of unprecedented scale.

Description

NewLimit is seeking an scientist with experience in liver biology and metabolism to join our Metabolism team. Our Metabolism team is developing reprogramming medicines to restore youthful function in aged hepatocytes in the context of metabolic disease. In this role, you will develop and perform assays for hepatocyte function, contribute to team decision making, and serve as a subject matter expert within NewLimit to enable our therapeutic development efforts.

As a Scientist on our team, you will:

- Collaborate with our Single Cell Technology, Epigenetic Editing, and Predictive Modeling teams to design, build, and test epigenetic reprogramming interventions for aged and diseased hepatocytes
- Develop assays to preclinical models of liver disease to measure hepatocyte function
- Evaluate epigenetic reprogramming payloads using in vivo functional assays to select therapeutic candidates
- Deliver epigenetic reprogramming perturbations to hepatocytes in vivo using multiple transgenic manipulation methods (e.g. viral vectors, lipid nanoparticles)
- Analyze and interpret experimental data to drive pre-clinical decision making

## Requirements

- Ph.D. in cell biology, molecular biology, biochemistry or a related field or equivalent industry experience (5+ years)
- Experience with primary liver cell isolation and functional characterization
- Experience working with mouse models of liver dysfunction
- Experience with transgenic manipulation of liver cells either ex vivo or in vivo (e.g. using viral vectors, nucleic acid delivery)
- Exceptional organizational skills, including detailed experimental record-keeping and the ability to manage multiple concurrent project

## Nice to have

- History of contributing to a drug development program at the pre-clinical or clinical development stage
- Experience leading the design and execution of pre-clinical studies in mouse models
- Experience with single cell genomics methods
- Experience with pooled screening approaches using bulk or single cell read-outs (e.g. CRISPR fitness screens, Perturb/CROP-seq)

## Benefits

NewLimit offers generous benefits to ensure our team can focus on our mission:

- Health, dental, and vision insurance
- 401(k) with company match
- Paid parental leave
- Industry-leading paid time off (PTO) — 20 days/year for all employees + holidays
- Meals and snacks on-site

Salary Range: $130,000 to $165,000. Compensation for the role will depend on a number of factors, including a candidate’s qualifications, skills, competencies, and experience. Learn more at: https://www.newlimit.com/careers

*This compensation and benefits information is based on Company's good faith estimate as of the date of publication and may be modified in the future

## About NewLimit

## Company Overview
- **One-liner**: NewLimit is a biotechnology company developing epigenetic reprogramming medicines to radically extend human healthspan by reversing cellular aging.
- **Entity Type**: Private (Series B)
- **Headquarters**: South San Francisco, California, United States
- **Founded**: 2022
- **Founders**: Jacob Kimmel (Co-founder & President), Brian Armstrong (Co-founder), Blake Byers (Co-founder)

## Core Business
- **Primary industry/industries**: Biotechnology, Epigenetic Reprogramming, Longevity Therapeutics, Drug Discovery
- **Target customers**: B2B (pharmaceutical partners, clinical development), B2C (ultimately patients with age-related diseases)
- **Mission or purpose statement**: To radically extend human healthspan by creating the first medicines that reverse cellular aging at the epigenetic level.

## Products & Services
- **Discovery Engine**: An AI-powered platform that designs epigenetic payloads to make old cells look and act young. It tests thousands of designs simultaneously using genomics and retrains models iteratively on new data.
- **Therapeutics (Pipeline)**: Medicines focused on restoring youthful function in the liver, immune system, and vasculature. Initial programs target diseases resembling accelerated aging, with the goal of restoring youthful metabolism, energy levels, resilience to disease, and cognition.

## Market Standing
- **Valuation/Market Cap**: Not publicly disclosed
- **Key Metric**: Total Funding of **$215M** (across three rounds); Annual Revenue estimated at **$12.8M** [linkedin.com](https://linkedin.com/company/newlimit)
- **Notable Investors/Partners**: Kleiner Perkins (led Series B), Valor Equity Partners, Quiet Capital, S32, Duke University Management Company, Liberty Mutual Investments, Fred Ehrsam, Elad Gil, Joe Lonsdale, Eric Schmidt, Garry Tan, Brian Armstrong, Blake Byers [newlimit.com](https://www.newlimit.com/company)
- **Growth Signals**: 44 employees (+40.5% YoY), 12 active job postings (+100% YoY), LinkedIn followers grew 157.6% in the past year, and the company closed a $130M Series B in May 2025 led by Kleiner Perkins [linkedin.com](https://linkedin.com/company/newlimit).

## Competitive Advantages
- **Proprietary AI Platform**: A frontier intelligence system that designs, tests, and retrains models on epigenetic reprogramming at unprecedented scale.
- **Scientific Moats**: Deep expertise in epigenetic reprogramming (a validated but complex mechanism for reversing cellular age); a team with backgrounds from Calico, UCSF, and Stanford.
- **Founding Team & Backing**: Co-founded by Brian Armstrong (CEO of Coinbase) and Blake Byers (early investor in OpenAI, Anthropic, Neuralink), providing deep capital access and a culture of ambitious, long-term execution.

## Strategic Focus
- **Current priorities**: Advancing pipeline programs into the clinic (Head of Clinical Development role is open); scaling the Discovery Engine; building the team across computational biology, immunology, and manufacturing.
- **Direction for growth**: Transition from a discovery-stage R&D company to a clinical-stage therapeutics company; generating large revenue streams to fund the mission; expanding into new cell types and disease areas.

## Why Work Here
- **Culture**: "Not for the faint of heart" — a high-performance, mission-focused team. No pure management roles; everyone executes. Values include safety then speed, clear communication, inherent optimism, independent thinking, and top talent in every seat [newlimit.com](https://www.newlimit.com/careers).
- **Remote/Hybrid/Office**: Likely on-site/hybrid given the lab-based nature of the work (headquarters in South San Francisco).
- **Notable Perks**: Competitive salaries, comprehensive health benefits (medical, dental, vision), equity packages, 401(k) with up to 4% match, generous parental leave, 20 days PTO + 15 holidays, free EV charging [newlimit.com](https://www.newlimit.com/careers).
- **Engineering Culture**: Strong emphasis on computational biology, machine learning, and functional genomics. The team spans both wet-lab and dry-lab disciplines, with a focus on building scalable methods and iterative data-driven discovery.

## Sources
1. [NewLimit Website](https://www.newlimit.com/)
2. [NewLimit Careers Page](https://www.newlimit.com/careers)
3. [NewLimit Company Page](https://www.newlimit.com/company)
4. [NewLimit Team Page](https://www.newlimit.com/team)
5. [NewLimit LinkedIn Page](https://www.linkedin.com/company/newlimit)

## Other roles at NewLimit

- [Senior/Research Associate, Single Cell Technology](https://feeny.ai/job/senior-research-associate-single-cell-technology-newlimit-south-san-francisco-mxftfy5f8ab1) — South San Francisco, CA
- [Senior Scientist / Scientist, In Vivo Pharmacology](https://feeny.ai/job/senior-scientist-scientist-in-vivo-pharmacology-newlimit-south-san-francisco-t4a3w08ps5rd) — South San Francisco, CA
- [Senior Manager, Lab Operations](https://feeny.ai/job/senior-manager-lab-operations-newlimit-south-san-francisco-2s9yfb1zrv9n) — South San Francisco, CA
- [Scientist, LNP-Drug Product Development](https://feeny.ai/job/scientist-lnp-drug-product-development-newlimit-south-san-francisco-nyvhkqvmdezz) — South San Francisco, CA
- [Director / Senior Director, Clinical Operations](https://feeny.ai/job/director-senior-director-clinical-operations-newlimit-south-san-francisco-3myq4z294a7c) — South San Francisco, CA
- [Laboratory Operations Specialist](https://feeny.ai/job/laboratory-operations-specialist-newlimit-south-san-francisco-mf010pr8xwk8) — South San Francisco, CA
- [Executive Assistant](https://feeny.ai/job/executive-assistant-newlimit-south-san-francisco-jznmrqh4wrvw) — South San Francisco, CA
- [Lead Security & Infrastructure Engineer](https://feeny.ai/job/lead-security-infrastructure-engineer-newlimit-south-san-francisco-zdar0wnmwbkn) — South San Francisco, CA
- [Principal/Senior Scientist, mRNA Process Sciences](https://feeny.ai/job/principal-senior-scientist-mrna-process-sciences-newlimit-south-san-francisco-bd0ye638wvxs) — South San Francisco, CA
- [Senior/Principal Scientist, Translational Biomarkers](https://feeny.ai/job/senior-principal-scientist-translational-biomarkers-newlimit-south-san-francisco-d7dtz5qkay5a) — South San Francisco, CA